The population density of Clovis, NM was 1,728 in 2018.
Population Density
Population Density is computed by dividing the total population by Land Area Per Square Mile.
Above charts are based on data from the U.S. Census American Community Survey | ODN Dataset | API -
Geographic and Population Datasets Involving Clovis, NM
- API
Deer Tick Surveillance: Adults (Oct to Dec) excluding Powassan virus: Beginning 2008
health.data.ny.gov | Last Updated 2024-05-01T18:05:44.000ZThis dataset provides the results from collecting and testing adult deer ticks, also known as blacklegged ticks, or by their scientific name <i>Ixodes scapularis</i>. Collection and testing take place across New York State (excluding New York City) from October to December, when adult deer ticks are most commonly seen. Adult deer ticks are individually tested for different bacteria and parasites, which includes the bacteria responsible for Lyme disease. These data should simply be used to educate people that there is a risk of coming in contact with ticks and tick-borne diseases. These data only provide adult tick infections at a precise location and at one point in time. Both measures, tick population density and percentage, of ticks infected with the specified bacteria or parasite can vary greatly within a very small area and within a county. These data should not be used to broadly predict disease risk for a county. Further below on this page you can find links to tick prevention tips, a video on how to safely remove a tick, and more datasets with tick testing results. Interactive charts and maps provide an easier way to view the data.
- API
Deer Tick Surveillance: Nymphs (May to Sept) excluding Powassan virus: Beginning 2008
health.data.ny.gov | Last Updated 2024-05-01T18:07:53.000ZThis dataset provides the results from collecting and testing nymph deer ticks, also known as blacklegged ticks, or by their scientific name <i>Ixodes scapularis</i>. Collection and testing take place across New York State (excluding New York City) from May to September, when nymph deer ticks are most commonly seen. Nymph deer ticks are individually tested for different bacteria and parasites, which includes the bacteria responsible for Lyme disease. These data should simply be used to educate people that there is a risk of coming in contact with ticks and tick-borne diseases. These data only provide nymph tick infections at a precise location and at one point in time. Both measures, tick population density and percentage, of ticks infected with the specified bacteria or parasite can vary greatly within a very small area and within a county. These data should not be used to broadly predict disease risk for a county. Further below on this page you can find links to tick prevention tips, a video on how to safely remove a tick, and more datasets with tick testing results. Interactive charts and maps provide an easier way to view the data.
- API
Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status
data.cdc.gov | Last Updated 2023-07-20T16:01:58.000ZData for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases
- API
Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status and Booster Dose
data.cdc.gov | Last Updated 2023-06-09T00:47:32.000ZData for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022. Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases
- API
Deer Tick Surveillance: Adults (Oct to Dec) Powassan Virus Only: Beginning 2009
health.data.ny.gov | Last Updated 2024-05-01T18:04:12.000ZThis dataset provides the results from collecting and testing adult deer ticks, also known as blacklegged ticks, or by their scientific name Ixodes scapularis. Collection and testing take place across New York State (excluding New York City) from October to December, when adult deer ticks are most commonly seen. Adult deer ticks are tested in “pools”, or groups of up to ten adult ticks per pool, for the Powassan virus, also known as Deer tick virus. These data should simply be used to educate people that there is a risk of coming in contact with ticks and tick-borne diseases. These data only provide adult tick minimum infection rates at a precise location and at a point in time. Both measures, tick population density and minimum infection percentages, can vary greatly within a very small area and within a county. These data should not be used to broadly predict disease risk for a county. Further below on this page you can find links to tick prevention tips, a video on how to safely remove a tick, and more datasets with tick testing results. Interactive charts and maps provide an easier way to view the data.
- API
Deer Tick Surveillance: Nymphs (May to Sept) Powassan Virus Only: Beginning 2009
health.data.ny.gov | Last Updated 2024-05-01T18:00:16.000ZThis dataset provides the results from collecting and testing nymph deer ticks, also known as blacklegged ticks, or by their scientific name <i>Ixodes scapularis</i>. Collection and testing take place across New York State (excluding New York City) from May to September, when nymph deer ticks are most commonly seen. Nymph deer ticks are tested in “pools”, or groups of up to ten adult ticks per pool, for the Powassan virus, also known as Deer tick virus. These data should simply be used to educate people that there is a risk of coming in contact with ticks and tick-borne diseases. These data only provide nymph tick minimum infection rates at a precise location and at one point in time. Both measures, tick population density and minimum infection percentages, can vary greatly within a very small area and within a county. These data should not be used to broadly predict disease risk for a county. Further below on this page you can find links to tick prevention tips, a video on how to safely remove a tick, and more datasets with tick testing results. Interactive charts and maps provide an easier way to view the data.
- API
New Brunswick Population Characteristics 1986 -2006 / Caractéristiques de la population du Nouveau-Brunswick 1986 -2006
gnb.socrata.com | Last Updated 2019-07-12T13:06:01.000ZAn overview of population totals for both urban and rural areas of New Brunswick / Un aperçu des totaux de population pour les zones urbaines et rurales du Nouveau-Brunswick
- API
NYCHA Development Data Book
data.cityofnewyork.us | Last Updated 2024-05-13T15:53:04.000ZContains the main body of the "Development Data Book". The Development Data Book lists all of the Authority's Developments alphabetically and includes information on the development identification numbers, program and construction type, number of apartments and rental rooms, population, number of buildings and stories, street boundaries, and political districts.
- API
Provisional COVID-19 death counts, rates, and percent of total deaths, by jurisdiction of residence
data.cdc.gov | Last Updated 2024-05-09T13:52:31.000ZThis file contains COVID-19 death counts, death rates, and percent of total deaths by jurisdiction of residence. The data is grouped by different time periods including 3-month period, weekly, and total (cumulative since January 1, 2020). United States death counts and rates include the 50 states, plus the District of Columbia and New York City. New York state estimates exclude New York City. Puerto Rico is included in HHS Region 2 estimates. Deaths with confirmed or presumed COVID-19, coded to ICD–10 code U07.1. Number of deaths reported in this file are the total number of COVID-19 deaths received and coded as of the date of analysis and may not represent all deaths that occurred in that period. Counts of deaths occurring before or after the reporting period are not included in the file. Data during recent periods are incomplete because of the lag in time between when the death occurred and when the death certificate is completed, submitted to NCHS and processed for reporting purposes. This delay can range from 1 week to 8 weeks or more, depending on the jurisdiction and cause of death. Death counts should not be compared across states. Data timeliness varies by state. Some states report deaths on a daily basis, while other states report deaths weekly or monthly. The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York, New York City, Puerto Rico; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington. Rates were calculated using the population estimates for 2021, which are estimated as of July 1, 2021 based on the Blended Base produced by the US Census Bureau in lieu of the April 1, 2020 decennial population count. The Blended Base consists of the blend of Vintage 2020 postcensal population estimates, 2020 Demographic Analysis Estimates, and 2020 Census PL 94-171 Redistricting File (see https://www2.census.gov/programs-surveys/popest/technical-documentation/methodology/2020-2021/methods-statement-v2021.pdf). Rates are based on deaths occurring in the specified week/month and are age-adjusted to the 2000 standard population using the direct method (see https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-08-508.pdf). These rates differ from annual age-adjusted rates, typically presented in NCHS publications based on a full year of data and annualized weekly/monthly age-adjusted rates which have been adjusted to allow comparison with annual rates. Annualization rates presents deaths per year per 100,000 population that would be expected in a year if the observed period specific (weekly/monthly) rate prevailed for a full year. Sub-national death counts between 1-9 are suppressed in accordance with NCHS data confidentiality standards. Rates based on death counts less than 20 are suppressed in accordance with NCHS standards of reliability as specified in NCHS Data Presentation Standards for Proportions (available from: https://www.cdc.gov/nchs/data/series/sr_02/sr02_175.pdf.).
- API
Rates of COVID-19 Cases or Deaths by Age Group and Updated (Bivalent) Booster Status
data.cdc.gov | Last Updated 2023-06-01T16:51:17.000ZData for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status Dataset and data visualization details: These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023. Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be